Table 1 Cohort demographics. Continuous variables are shown as median (interquartile range). Significance of demographic data was determined by Fisher’s exact test for categorical data and the Wilcoxon rank-sum test for continuous data
CD (n=88) | Control (n=110) | p-value | |
|---|---|---|---|
Gender | |||
Male | 47% | 70% | 0.001 |
Female | 53% | 30% | |
Race/ethnicity | |||
Caucasian | 91% | 95% | 0.78 |
Hispanic | 3% | 0% | |
African-American | 2% | 1% | |
Asian/Pacific Islander | 3% | 2% | |
Non-white Hispanic | 3% | 3% | |
Age | 41 (29–53) | 64 (57–73) | 2 × 10−16 |
BMI | 23.5 (21.0–26.2) | 25.8 (23.6–27.8) | 0.0001 |
GRS | 0.35 (−0.22–1.0) | −0.07 (−0.80–0.68) | 0.003 |
Age at diagnosis | 24 (19–33) | ||
Duration (years) | 11 (6–17) | ||
CD location | |||
L1 = Ileal | 15% | ||
L2 = Colonic | 11% | ||
L3 = Ileocolonic | 74% | ||
Upper GI involvement | 8% | ||
Perianal disease | 26% | ||
CD behavior | |||
B1 = Non-stricturing | 34% | ||
B2 = Stricturing | 32% | ||
B3 = Penetrating | 34% | ||
Medication | |||
5-aminosalicylate | 47% | ||
Immunomodulator | 29% | ||
Biologic (anti-TNF) | 57% | ||